Home Biosimilar Antibodies Metabolism ROR Zilovertamab (Anti-ROR1)
For research use only. Not for use in humans.

Zilovertamab (Anti-ROR1)

Synonyms: NTRKR1， ROR1

Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD.

Zilovertamab (Anti-ROR1)

Click to purchase the isotype control of Zilovertamab (Anti-ROR1)

Quality Control

Batch: A236601 Purity: 99% Protein concentration: 15.9mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation RORγ
S18-000003 0
TMP778 0
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD.

Product Details

CAS No. 2485779-13-1
Molecular Weight 146.14 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06717347 RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Dr Diffuse Large B-Cell Lymphoma Merck Sharp & Dohme LLC 2025-01-27 PHASE3
NCT05458297 ACTIVE_NOT_RECRUITING Drug: Nemtabrutinib Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma; Richter Transformation Lymphoma Merck Sharp & Dohme LLC 2022-07-21 PHASE2
NCT05406401 ACTIVE_NOT_RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Dr Lymphoma, Large B-Cell, Diffuse (DLBCL) Merck Sharp & Dohme LLC 2022-07-14 PHASE2
NCT06395103 RECRUITING B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Neuroblastoma; Ewing Sarcoma Merck Sharp & Dohme LLC 2024-08-16 PHASE1; PHASE2
NCT05562830 RECRUITING Urothelial Carcinoma Merck Sharp & Dohme LLC 2022-11-16 PHASE1; PHASE2
NCT06890884 RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Dr Lymphoma, Large B-Cell, Diffuse Merck Sharp & Dohme LLC 2025-04-11 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.